Dermatology Times

OCTOBER 13, 2023

Almirall presented new data on lebrikizumab at EADV related to clinical improvements and clinically-meaningful treatment responses among patients with atopic dermatitis.

Clinic 74

Clinic Dermatitis Treatments 74

Dermatology Times

JULY 3, 2024

Experts on atopic dermatitis weigh the risks and rewards of systemic treatments for pregnant patients and provide clinical insights on monitoring for adverse effects associated with dupilumab.

Dermatitis 36

Dermatitis Treatments Clinic 36

First Derm

FEBRUARY 21, 2024

Treatment Approaches Vary : Treatment for eczema includes emollients and topical steroids, while psoriasis may be treated with light therapy, systemic medications, and biologics, emphasizing the need for personalized care. Contact dermatitis from metals, latex, chemicals. 2] Why is Eczema Considered a Chronic Condition?

Eczema 59

Eczema Dermatitis Management Medical 59

The Dermatology Digest

JANUARY 22, 2024

s ZORYVE topical foam, 0.3%, is now officially available for the treatment of seborrheic dermatitis. Food and Drug Administration (FDA) approved ZORYVE foam for the treatment of seborrheic dermatitis in individuals 9 years of age and older on December 15, 2023. Arcutis Biotherapeutics, Inc.’s

Dermatitis 78

Dermatitis Treatments Innovations Clinic 78

Dermatology Times

NOVEMBER 28, 2023

A phase 1 study found that RPT193 monotherapy led to greater improvements in clinical efficacy than treatment with a placebo.

Clinic 78

Clinic Dermatitis Treatments 78

Dermatology Times

APRIL 19, 2024

James Del Rosso, DO, Brad Glick, DO, MPH, FAAD, and Lisa Swanson, MD, FAAD, address the demand for non-steroidal treatment alternatives while navigating the individualization of data interpretation regarding these treatments.

Treatments 36

Treatments Clinic Dermatitis 36

The Dermatology Digest

FEBRUARY 26, 2024

Shared-decision making focused on weighing risks versus benefits is key when choosing the most appropriate systemic atopic dermatitis (AD) treatment for a patient, according to new research presented at the 2024 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in Washington, DC. some of the JAK inhibitors).

Treatments 74

Treatments Dermatitis Pharmaceutical Clinic 74

The Dermatology Digest

APRIL 7, 2024

A newly developed therapeutic ladder can help guide dermatologists and patients on the use of nonsteroidal treatment options for atopic dermatitis (AD). Nonsteroidal treatment options for AD have rapidly expanded in recent years with the development of phosphodiesterase-4 inhibitors, biologics, and Janus kinase (JAK) inhibitors.

Treatments 77

Treatments Dermatitis Therapy Safety 77

Dermatology Times

JUNE 19, 2024

Dermatologists provide clinical insights on how they discuss atopic dermatitis treatment options, considerations, and safety concerns with patients who are pregnant or of childbearing age.

Treatments 36

Treatments Dermatitis Safety Clinic 36

MedEsthetics

AUGUST 11, 2023

atopic dermatitis, acne, inflammatory conditions, skincare, acne treatment, peptide, medical aesthetics, clinical trials, phase 1 study, British journal of dermatology

Dermatitis 60

Dermatitis Skincare Clinic Medical 60

Dermatology Times

AUGUST 20, 2024

A key opinion leader in the field of dermatology examines treatment strategies and medication sequencing for atopic and hand dermatitis in a 20-year-old female patient, focusing on clinical considerations and optimal management approaches.

Dermatitis 36

Dermatitis Management Clinic Medical 36

Dermatology Times

FEBRUARY 6, 2024

Researchers explored the efficacy of a multistep treatment strategy in a younger patient population.

Clinic 81

Clinic Dermatitis Treatments 81

Dermatology Times

NOVEMBER 22, 2023

Connect Biopharma announced positive long-term data from its China pivotal trial.

Clinic 73

Clinic Dermatitis Treatments 73

The Dermatology Digest

NOVEMBER 2, 2023

Peter Lio discusses complementary approaches to skin disease treatment, including risks, benefits, and evidence. Peter Lio, MD, Clinical Assistant Professor, Dermatology and Pediatrics, Feinberg School of Medicine, Northwestern University, Evanston, Ill. That said, natural treatments are not risk free, he said. “We

Treatments 66

Treatments Dermatitis Dermatology Eczema 66

The Dermatology Digest

FEBRUARY 14, 2024

Food and Drug Administration (FDA) has accepted Galderma’s Biologics License Applications for nemolizumab for the treatment of patients with prurigo nodularis (PN) and for adolescents and adults with moderate to severe atopic dermatitis (AD). Galderma is planning for multiple regulatory submissions in 2024. “The

Dermatitis 78

Dermatitis Clinic Safety Dermatology 78

The Dermatology Digest

MARCH 13, 2024

Adam Friedman, MD, Professor and Chair of Dermatology at George Washington School of Medicine and Health Sciences in Washington, DC, shares his excitement about chronic spontaneous urticaria (CSU) treatments coming down the pike including remibrutinib, Novartis’ investigational oral Bruton’s tyrosine kinase inhibitor.

Treatments 36

Treatments Dermatitis Dermatology Eczema 36

First Derm

APRIL 5, 2024

Factors affecting adherence include socioeconomic status, treatment complexity, and the specific skin condition being treated. Strategies to improve adherence range from using eHealth tools and educational resources to simplifying treatment regimens.

Dermatology 59

Dermatology Treatments Education Medical 59

The Dermatology Digest

MARCH 10, 2024

Silverberg, MD Molluscum Contagiosum appears to be on the rise and often travels with atopic dermatitis (AD). Lio, MD, a Clinical Assistant Professor of Dermatology and Pediatrics at Northwestern University Feinberg School of Medicine and a partner at Medical Dermatology Associates of Chicago, discusses which ones works best.

Treatments 36

Treatments Pharmaceutical Dermatitis Eczema 36

First Derm

DECEMBER 28, 2023

Treatment Options : Explore a variety of effective treatments available for each condition. Uncover the diverse causes behind this common skincare concern, discover effective treatments, and gain valuable insights into maintaining a healthy, hydrated and vibrant complexion. Online Dermatologist Dry Patches on Your Face?

Treatments 45

Treatments Eczema Dermatitis Skin Health 45

The Dermatology Digest

MARCH 10, 2024

Silverberg, MD Molluscum Contagiosum appears to be on the rise and often travels with atopic dermatitis (AD). Lio, MD, a Clinical Assistant Professor of Dermatology and Pediatrics at Northwestern University Feinberg School of Medicine and a partner at Medical Dermatology Associates of Chicago, discusses which ones works best.

Treatments 36

Treatments Dermatitis Eczema Dermatology 36

The Dermatology Digest

JANUARY 14, 2024

People with seborrheic dermatitis who don’t use topical steroids are 3.5 The research was presented at the 2024 Winter Clinical Dermatology Conference – Hawaii in Honolulu. The research was presented at the 2024 Winter Clinical Dermatology Conference – Hawaii in Honolulu. Zoryve foam; 48.3% of the total study population).

Dermatitis 72

Dermatitis Dermatology Office Safety 72

First Derm

MARCH 22, 2024

Eczema herpeticum Medically reviewed by The Dermatologists and written by Dr. Alexander Börve In A Nutshell What It Is : Skin infection marked by fever and clusters of itchy blisters, often complicating atopic dermatitis. Who’s at Risk : Affects both genders and all ages, but more common in infants and children with atopic dermatitis.

Eczema 52

Eczema Dermatitis Clinic Medical 52

Dermatology Times

JANUARY 12, 2024

Ten posters at the Winter Clinical Hawaii and Maui Derm Conferences will showcase investigational data to expand treatment options for patients with atopic dermatitis and chronic hand eczema.

Eczema 74

Eczema Dermatitis Clinic Treatments 74

First Derm

OCTOBER 9, 2023

Online Dermatologist Rash on Butt: Causes, Diagnosis, and Treatment Causes | Diagnosis | Seeking Medical Attention | Home Remedies | Treatments | Prevention A rash or sores on your buttocks can occur for a variety of causes. Contact dermatitis Contact dermatitis is a common type of rash.

Treatments 45

Treatments Dermatitis Irritation Eczema 45

Dermatology Times

JANUARY 30, 2024

Positive results in preclinical animal trials of DPT0218 may lead to advances in clinical treatment of autoimmune diseases.

Dermatitis 74

Dermatitis Clinic Treatments 74

The Dermatology Digest

MARCH 13, 2024

Silverberg, MD, Chief of Pediatric Dermatology for the Mount Sinai Health System in New York, reviews the rationale for treating Molluscum Contagiosum and shares updates on available treatments including disruptive techniques and the newly approved Zelsuvmi (berdazimer topical gel, 10.3% (Zelsuvmi, Ligand) cantharidin (Ycanth, Verrica).

Treatments 36

Treatments Dermatitis Dermatology Eczema 36

The Dermatology Digest

JUNE 4, 2024

Waldman Department of Dermatology and Professor of Dermatology and Immunology at the Icahn School of Medicine at Mount Sinai in New York City, received the Paul Ehrlich Award for Experimental Research at the 2024 European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress in Valencia, Spain.

Eczema 36

Eczema Dermatitis Clinic Sensitive Skin 36

The Dermatology Digest

JANUARY 29, 2024

Food and Drug Administration (FDA) for treatment of seborrheic dermatitis in adult and pediatric patients 9 years of age and older in December 2023. It is the first drug approved for seborrheic dermatitis with a new mechanism of action in over two decades. in seborrheic dermatitis. in seborrheic dermatitis.

Dermatitis 74

Dermatitis Safety Dermatology Treatments 74

The Dermatology Digest

MARCH 11, 2024

Adding narrowband ultraviolet B phototherapy to treatment with ritlecitinib (Litfulo, Pfizer) in vitiligo may improve patient outcomes. Silverberg, MD Molluscum Contagiosum appears to be on the rise and often travels with atopic dermatitis (AD). Watch Now The Lowdown on Molluscum Nanette B.

Dermatitis 69

Dermatitis Eczema Dermatology Pharmaceutical 69

The Dermatology Digest

JULY 10, 2024

for use in moderate to severe atopic dermatitis (AD) in the NHS England. The interleukin-13 blocker is indicated for the treatment of adult and adolescent patients (12 years and older with a body weight of at least 40 kg) with moderate to severe AD, who are candidates for systemic therapy.

Dermatitis 36

Dermatitis Safety Dermatology Marketing 36

The Dermatology Digest

DECEMBER 15, 2023

Food and Drug Administration (FDA) has given its nod to topical roflumilast foam (Zoryve, Arcutis) for seborrheic dermatitis. The PDE4 inhibitor is the first topical treatment for seborrheic dermatitis with a new mechanism of action in more than 20 years. in seborrheic dermatitis.

Dermatitis 36

Dermatitis Safety Clinic Medical 36

US Dermatologt Partners

MAY 29, 2024

Wofford will discuss the common causes of white toenails and recommended treatment options. Causes of White Toenails According to Dr. Wofford, “There are many causes of white toenails , but the two most common, representing over 90% of all cases that I see in my clinic, are trauma and nail fungus (onychomycosis).

Treatments 36

Treatments Dermatology Moisturization Medical 36

First Derm

JULY 2, 2024

Online Dermatologist Sweating and Eczema: How to Manage Flare-Ups Eczema and Sweat | Symptoms of eczema | Physiology | How Sweating Affects Eczema | Triggers for Eczema | Related conditions | Managing Sweat to Prevent Eczema Flare-Ups | Treatment Key Takeaways Eczema, particularly atopic dermatitis, flares up with triggers like sweat.

Eczema 59

Eczema Management Dermatitis Irritation 59

The Dermatology Digest

APRIL 30, 2024

Eli Lilly has resubmitted its Biologics License Application (BLA) for Lebrikizumab for the treatment of moderate to severe atopic dermatitis (AD), with regulatory action anticipated in the second half of 2024. There were no concerns with lebrikizumab’s clinical data package, safety, or label.

Dermatitis 36

Dermatitis Safety Clinic Dermatology 36

The Dermatology Digest

MAY 2, 2024

Aslan and Zenyaku are teaming up to explore how eblasakimab’s mechanism of action differs from that of other biologic therapies for atopic dermatitis (AD). This new agreement expands upon the commercial agreement that Aslan signed with Zenyaku in June 2023 for the development and commercialization of eblasakimab in Japan.

Pharmaceutical 74

Pharmaceutical Dermatitis Office Clinic 74

The Dermatology Digest

AUGUST 13, 2024

Food and Drug Administration (FDA) has approved nemolizumab (Nemluvio, Galderma) as a pre-filled pen for subcutaneous injection for the treatment of adults with prurigo nodularis. First, it represents the first approved clinical use of anti-IL31 technology,” he says.“Second, I’m delighted that Nemluvio has received U.S.

Dermatitis 36

Dermatitis Safety Clinic Dermatology 36

The Dermatology Digest

MARCH 8, 2024

Tapinarof cream, 1% (Vtama, Dermavant) shows “consistent and high” efficacy in atopic dermatitis (AD) patients across different self-reported racial categories and Fitzpatrick skin types, according to two Phase 3 studies presented at the American Academy of Dermatology’s 2024 meeting in San Diego, CA.

Dermatitis 36

Dermatitis Clinic Eczema Dermatology 36